vTv Therapeutics Inc.
NASDAQ:VTVT · NASDAQ Capital Market
+$0.50 today
Vol 0.06M · Avg 0.05M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:VTVT · Revenue to Net Income
Key Ratios
Analysis
$36.8M of revenue converted into $2.3M of net income for the selected period. Gross margin is 25.0% and net margin is 16.4%, showing how much revenue survives after costs and taxes. EPS is $0.02, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 -100.0% | $1.0M | $0 -100.0% | $2.0M -49.6% | $4.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 -100.0% | $1.0M | $0 -100.0% | $2.0M -49.6% | $4.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | 100.0% | — | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $17.9M +54.7% | $11.5M -15.1% | $13.6M +10.0% | $12.4M -7.3% | $13.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $14.9M +9.5% | $13.7M +14.6% | $11.9M -2.4% | $12.2M -1.2% | $12.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $32.8M +30.2% | $25.2M -1.2% | $25.5M +3.8% | $24.6M -4.3% | $25.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $16.0K -82.0% | $89.0K -1.1% | $90.0K -2.2% | $92.0K +3.4% | $89.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$31.1M -37.9% | -$22.5M +12.9% | -$25.9M -4.4% | -$24.8M -41.4% | -$17.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | -2214.0% | — | -1227.3% -789.9pp | -437.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$32.8M -35.7% | -$24.2M +5.2% | -$25.5M -13.1% | -$22.5M -4.1% | -$21.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | -2377.6% | — | -1116.9% -576.1pp | -540.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.9M +19.5% | $1.6M +231.6% | $472.0K +34.1% | $352.0K +35100.0% | $1.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $6.0K | $0 -100.0% | $13.0K -13.3% | $15.0K +25.0% | $12.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.7M +9.7% | $1.6M +439.4% | -$464.0K +80.1% | -$2.3M -157.7% | $4.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$31.1M -37.5% | -$22.6M +12.9% | -$26.0M -4.4% | -$24.9M -41.2% | -$17.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | -2222.7% | — | -1232.6% -792.7pp | -439.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 -100.0% | $100.0K | $0 -100.0% | $200.0K +73.9% | $115.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$27.0M -46.1% | -$18.5M +8.8% | -$20.3M -5.7% | -$19.2M -47.6% | -$13.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | -1815.3% | — | -949.7% -625.4pp | -324.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +0.0% | -$3 +67.0% | -$10 +2.7% | -$10 -20.4% | -$8 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +0.0% | -$3 +67.0% | -$10 +2.7% | -$10 -20.4% | -$8 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $8.4M +46.0% | $5.8M +176.8% | $2.1M +8.6% | $1.9M +22.6% | $1.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $8.4M +46.0% | $5.8M +176.8% | $2.1M +8.6% | $1.9M +22.6% | $1.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Fortress Biotech, Inc.
NASDAQ:FBIO
$100.49M
OS Therapies Incorporated
AMEX:OSTX
$81.06M
Gain Therapeutics, Inc.
NASDAQ:GANX
$78.06M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$70.28M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$69.75M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$63.56M
MiNK Therapeutics, Inc.
NASDAQ:INKT
$58.99M
CervoMed Inc.
CRVO
$38.79M
Werewolf Therapeutics, Inc.
HOWL
$17.18M
IO Biotech, Inc.
IOBT
$885,690.00
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does VTVT generate?
vTv Therapeutics Inc. (VTVT) reported $0.00 of revenue in fiscal 2025.
Is VTVT profitable?
vTv Therapeutics Inc. (VTVT) reported -$26,974,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.